Call for CSFD members

European Commission has opened the Call for applications for members of its expert group the Civil Society Forum on Drugs (CSFD). As the membership of the Group will be completely renewed for 2021-2023, the Commission is calling for applications with a view to selecting members of the group.

The Forum membership comprises 45 civil society organisations coming from across Europe and representing a variety of fields of drug policy, and a variety of stances within those fields.  Its purpose is to provide a broad platform for a structured dialogue between the Commission and the European civil society which supports drug policy formulation and implementation through practical advice.

Members shall be organisations in the broad sense of the word, including associations, Non-Governmental Organisations (NGOs), trade unions, universities and research institutes, and other organisations, if relevant to EU drugs policy, and individuals appointed in a personal capacity.

The Call is available following this link>>>.


Make Drug Policy a Priority

Press Release

On 5 December 2019, the EU Civil Society Forum on Drugs (CSFD), an expert group of the European Commission, organized a seminar for Members of the European Parliament (MEPs) entitled ‘The Future of European Drug Policy’.

The event comes at a time when the EU is facing significant challenges in tackling the illicit drug market. Despite the EU’s efforts to counter the drug problem, drug trafficking and production remain among the most profitable criminal activities in the region, while the health and social harms associated with drug use continue to rise, with more than 8.000 drug-related deaths reported in 2019. Drug-related issues affect millions of people within the EU, bringing with them complex health, security, social and criminal justice issues.

The expiry of the current European Drugs Strategy (2013 – 20) and Action Plan (2017 – 20) represent a key opportunity to be seized by the EU. It is a chance to review successes and failures of European drug policy and to build on the learnings and challenges from the last decade, by continuing to prioritize a drug policy approach grounded in the principles of public health and human rights.

However, civil society expressed concerns that the EU is failing to recognize the importance and cross-cutting nature of drug policy and is now deprioritizing the issue.

During the seminar, the CSFD urged MEPs to undertake the following actions: prioritize health challenges associated with drug use, uphold human rights above all, discuss ongoing debates and policy shifts associated with cannabis regulation, ensure that funding is allocated for drug-related projects beyond 2020 and consider creating an informal group of MEPs interested in European drug policy to track key developments in European drug policy.